loading

Vyne Therapeutics Inc (VYNE) 最新ニュース

pulisher
Feb 21, 2025

HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

VYNE Therapeutics to Participate in March Investor Conferences - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

Can VYNE Therapeutics' March Investor Conferences Reveal New Strategic Directions? - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment - Nasdaq

Feb 19, 2025
pulisher
Feb 19, 2025

Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details - StockTitan

Feb 19, 2025
pulisher
Feb 17, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN

Feb 17, 2025
pulisher
Jan 20, 2025

VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World

Jan 20, 2025
pulisher
Jan 17, 2025

Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia

Jan 17, 2025
pulisher
Jan 17, 2025

Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus.com

Jan 17, 2025
pulisher
Jan 14, 2025

VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail

Jan 13, 2025
pulisher
Jan 10, 2025

Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World

Jan 10, 2025
pulisher
Jan 07, 2025

VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo - Yahoo Finance

Jan 07, 2025
pulisher
Jan 07, 2025

VYNE Therapeutics’ (VYNE) Buy Rating Reaffirmed at HC Wainwright - Defense World

Jan 07, 2025
pulisher
Jan 06, 2025

Forecasting The Future: 4 Analyst Projections For VYNE Therapeutics - Benzinga

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics' (VYNE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo - Marketscreener.com

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluat - WICZ

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics Completes Phase 2b Trial Enrollment for Novel Vitiligo Treatment VYN201 - StockTitan

Jan 06, 2025
pulisher
Jan 06, 2025

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo - Yahoo Finance

Jan 06, 2025
pulisher
Jan 02, 2025

VYNE stock soars to 52-week high, touches $3.43 By Investing.com - Investing.com South Africa

Jan 02, 2025
pulisher
Jan 02, 2025

VYNE stock soars to 52-week high, touches $3.43 - Investing.com

Jan 02, 2025
pulisher
Dec 26, 2024

VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202 - Defense World

Dec 26, 2024
pulisher
Dec 24, 2024

H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data - Yahoo Finance

Dec 24, 2024
pulisher
Dec 24, 2024

VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Dec 24, 2024
pulisher
Dec 23, 2024

VYNE Therapeutics Reports Positive Phase 1a MAD Data for BD2-Selective BET Inhibitor VYN202 - Dermatology Times

Dec 23, 2024
pulisher
Dec 23, 2024

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - The Manila Times

Dec 23, 2024
pulisher
Dec 15, 2024

Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Drops By 37.1% - Defense World

Dec 15, 2024
pulisher
Dec 12, 2024

VYNE Therapeutics Sees Strong Shareholder Support for Growth - TipRanks

Dec 12, 2024
pulisher
Nov 29, 2024

Prurigo Nodularis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therap - The Globe and Mail

Nov 29, 2024
pulisher
Nov 24, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 24, 2024
pulisher
Nov 19, 2024

VYNE Therapeutics initiated with a Buy at BTIG on I&I potential - Yahoo Finance

Nov 19, 2024
pulisher
Nov 18, 2024

BTIG Initiates Coverage of VYNE Therapeutics (VYNE) with Buy Recommendation - MSN

Nov 18, 2024
pulisher
Nov 11, 2024

VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 11, 2024
pulisher
Nov 09, 2024

VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 09, 2024
pulisher
Nov 08, 2024

VYNE Therapeutics Advances Clinical Pipeline in Q3 2024 - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

VYNEVYNE Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

VYNE Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 07, 2024
pulisher
Nov 07, 2024

VYNE Therapeutics Reports Strong Pipeline Progress, $70.2M Cash Position Despite Q3 Loss | VYNE Stock News - StockTitan

Nov 07, 2024
pulisher
Oct 09, 2024

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate - Simply Wall St

Oct 09, 2024
pulisher
Sep 26, 2024

We Think VYNE Therapeutics (NASDAQ:VYNE) Needs To Drive Business Growth Carefully - Yahoo Finance

Sep 26, 2024
pulisher
Sep 24, 2024

VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

Shapiro Capital Management LLC Makes New Investment in NCR Voyix Co. (NYSE:VYX) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

(VYX) Long Term Investment Analysis - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Engine Capital Management LP Purchases Shares of 78,691 NCR Voyix Co. (NYSE:VYX) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

ZIGUP plc Optimistic as Vehicle Supply Improves - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

ZIGUP plc Optimistic as Vehicle Supply Rises - TipRanks

Sep 24, 2024
pulisher
Sep 23, 2024

Wix Is Set for Growth With Expanding Margins and Cash Flow, Analyst Upgrades Stock - Benzinga

Sep 23, 2024
pulisher
Sep 23, 2024

What is Voyager Therapeutics Inc (VYGR) Stock Return on Shareholders’ Capital? - SETE News

Sep 23, 2024
pulisher
Sep 23, 2024

Wix, GoDaddy in spotlight as Piper Sandler changes ratings on pair - Seeking Alpha

Sep 23, 2024
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):